Mangalam Drugs’ Performance Analyzed

Mangalam Drugs and Organics had a tough quarter. Their sales dropped significantly, falling by 34% to just 58.38 crore rupees. This resulted in a substantial loss of 9.84 crore rupees.

Key Points

• Sales plummeted 34%, reaching 58.38 crore rupees this quarter.
• The company reported a net loss of 9.84 crore rupees.
• Previous quarter profits were 1.29 crore rupees, a positive contrast.
• Operating profit margin decreased to -2.45%, signaling financial strain.
• Profit before tax (PBDT) fell sharply to -5.37 crore rupees.
• Net profit significantly decreased from 1.29 crore to 9.84 crore rupees.

Financial Details Breakdown

Let’s look at the numbers more closely. In the quarter that just ended (December 2025), the company made 58.38 crore rupees in sales. This is a huge decrease from the 88.55 crore rupees they made the previous quarter.

This drop in sales led to a net loss of 9.84 crore rupees. Previously, they had made a profit of 1.29 crore rupees.

Profitability Issues

The company’s operating profit margin was -2.45%, which means they weren’t making enough money from what they were selling to cover their costs. Their profit before tax (PBDT) was -5.37 crore rupees – a significant decrease compared to 5.42 crore rupees.

The final net profit came to 9.84 crore rupees, a stark contrast to the previous quarter’s profit of 1.29 crore rupees.

These results show a clear need to address the company’s financial challenges quickly.

Ultimately, Mangalam Drugs and Organics requires immediate strategic adjustments to regain profitability.